Metropolitan Life Insurance CO Revance Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

  • $2.27 Billion
  • Q1 2024

A detailed history of Metropolitan Life Insurance CO transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Metropolitan Life Insurance CO holds 3,633 shares of RVNC stock, worth $9,336. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,633
Previous 4,832 24.81%
Holding current value
$9,336
Previous $42,000 59.52%
% of portfolio
0.0%
Previous 0.0%

Shares

53 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
SELL
$4.65 - $9.31 $5,575 - $11,162
-1,199 Reduced 24.81%
3,633 $17,000
Q3 2023

Nov 14, 2023
BUY
$11.47 - $25.07 $3,154 - $6,894
275 Added 6.03%
4,832 $55,000
Q2 2023

Aug 10, 2023
BUY
$24.7 - $37.61 $4,717 - $7,183
191 Added 4.37%
4,557 $115,000
Q1 2023

May 15, 2023
SELL
$18.36 - $35.27 $11,493 - $22,079
-626 Reduced 12.54%
4,366 $140,000
Q4 2022

Jun 14, 2023
BUY
$18.32 - $30.66 $11,468 - $19,193
626 Added 14.34%
4,992 $92.2 Million
Q4 2022

Mar 30, 2023
BUY
$18.32 - $30.66 $12,402 - $20,756
677 Added 15.69%
4,992 $92,000
Q4 2022

Feb 15, 2023
BUY
$18.32 - $30.66 $12,402 - $20,756
677 Added 15.69%
4,992 $92,000
Q3 2022

Jun 14, 2023
SELL
$14.33 - $28.47 $730 - $1,451
-51 Reduced 1.17%
4,315 $117 Million
Q3 2022

Mar 30, 2023
SELL
$14.33 - $28.47 $6,577 - $13,067
-459 Reduced 9.61%
4,315 $116,000
Q3 2022

Nov 14, 2022
SELL
$14.33 - $28.47 $6,577 - $13,067
-459 Reduced 9.61%
4,315 $117,000
Q2 2022

Jun 20, 2023
BUY
$11.52 - $20.4 $4,700 - $8,323
408 Added 9.34%
4,774 $65,000
Q1 2022

Jun 20, 2023
BUY
$12.36 - $20.31 $5,042 - $8,286
408 Added 9.34%
4,774 $93,000
Q1 2022

Mar 30, 2023
SELL
$12.36 - $20.31 $150,569 - $247,416
-12,182 Reduced 71.84%
4,774 $93,000
Q1 2022

May 12, 2022
SELL
$12.36 - $20.31 $150,569 - $247,416
-12,182 Reduced 71.84%
4,774 $93,000
Q4 2021

Jun 21, 2023
BUY
$12.46 - $27.87 $156,871 - $350,883
12,590 Added 288.36%
16,956 $276,000
Q4 2021

Mar 30, 2023
SELL
$12.46 - $27.87 $33,642 - $75,249
-2,700 Reduced 13.74%
16,956 $276,000
Q4 2021

Feb 15, 2022
SELL
$12.46 - $27.87 $33,642 - $75,249
-2,700 Reduced 13.74%
16,956 $277,000
Q3 2021

Jun 21, 2023
BUY
$25.78 - $33.21 $394,176 - $507,780
15,290 Added 350.21%
19,656 $547,000
Q3 2021

Mar 30, 2023
BUY
$25.78 - $33.21 $11,317 - $14,579
439 Added 2.28%
19,656 $547,000
Q3 2021

Nov 15, 2021
BUY
$25.78 - $33.21 $11,317 - $14,579
439 Added 2.28%
19,656 $548,000
Q2 2021

Jun 21, 2023
BUY
$26.8 - $31.84 $398,006 - $472,855
14,851 Added 340.15%
19,217 $569,000
Q2 2021

Mar 30, 2023
BUY
$26.8 - $31.84 $60,487 - $71,862
2,257 Added 13.31%
19,217 $569,000
Q2 2021

Aug 16, 2021
BUY
$26.8 - $31.84 $514,560 - $611,328
19,200 Added 112941.18%
19,217 $570,000
Q1 2021

Jun 26, 2023
BUY
$24.03 - $29.97 $302,633 - $377,442
12,594 Added 288.46%
16,960 $474 Million
Q1 2021

Mar 30, 2023
SELL
$24.03 - $29.97 $14,466 - $18,041
-602 Reduced 3.43%
16,960 $474,000
Q1 2021

May 14, 2021
SELL
$24.03 - $29.97 $421,606 - $525,823
-17,545 Reduced 99.9%
17 $474,000
Q4 2020

Jun 22, 2023
BUY
$23.41 - $28.34 $308,918 - $373,974
13,196 Added 302.24%
17,562 $497,000
Q3 2020

Jun 26, 2023
BUY
$23.23 - $34.3 $306,543 - $452,622
13,196 Added 302.24%
17,562 $441,000
Q2 2020

Jun 26, 2023
BUY
$12.6 - $26.55 $166,269 - $350,353
13,196 Added 302.24%
17,562 $428,000
Q2 2020

Mar 30, 2023
BUY
$12.6 - $26.55 $24,897 - $52,462
1,976 Added 12.68%
17,562 $428,000
Q2 2020

Aug 14, 2020
BUY
$12.6 - $26.55 $24,897 - $52,462
1,976 Added 12.68%
17,562 $429,000
Q1 2020

Jul 12, 2023
BUY
$12.46 - $27.81 $139,801 - $312,028
11,220 Added 256.99%
15,586 $230,000
Q1 2020

Mar 30, 2023
BUY
$12.46 - $27.81 $16,185 - $36,125
1,299 Added 9.09%
15,586 $230,000
Q1 2020

May 15, 2020
BUY
$12.46 - $27.81 $16,185 - $36,125
1,299 Added 9.09%
15,586 $231,000
Q4 2019

Jul 12, 2023
BUY
$11.66 - $20.15 $115,678 - $199,908
9,921 Added 227.23%
14,287 $231,000
Q4 2019

Mar 30, 2023
SELL
$11.66 - $20.15 $21,582 - $37,297
-1,851 Reduced 11.47%
14,287 $231,000
Q4 2019

Feb 14, 2020
SELL
$11.66 - $20.15 $21,582 - $37,297
-1,851 Reduced 11.47%
14,287 $232,000
Q3 2019

Jul 12, 2023
BUY
$10.22 - $14.5 $120,309 - $170,694
11,772 Added 269.63%
16,138 $209,000
Q3 2019

Mar 30, 2023
BUY
$10.22 - $14.5 $48,054 - $68,179
4,702 Added 41.12%
16,138 $209,000
Q3 2019

Nov 14, 2019
BUY
$10.22 - $14.5 $48,054 - $68,179
4,702 Added 41.12%
16,138 $210,000
Q2 2019

Jul 12, 2023
BUY
$10.67 - $15.49 $75,436 - $109,514
7,070 Added 161.93%
11,436 $148,000
Q1 2019

Jul 13, 2023
BUY
$15.4 - $20.39 $108,878 - $144,157
7,070 Added 161.93%
11,436 $180,000
Q1 2019

Mar 30, 2023
BUY
$15.4 - $20.39 $99,237 - $131,393
6,444 Added 129.09%
11,436 $180,000
Q1 2019

May 16, 2019
SELL
$15.4 - $20.39 $2.06 Million - $2.73 Million
-133,718 Reduced 92.12%
11,436 $180,000
Q1 2019

May 15, 2019
BUY
$15.4 - $20.39 $2.07 Million - $2.74 Million
134,279 Added 1234.75%
145,154 $27.9 Million
Q4 2018

Jul 13, 2023
BUY
$18.06 - $24.96 $117,552 - $162,464
6,509 Added 149.08%
10,875 $218,000
Q4 2018

Feb 14, 2019
BUY
$18.06 - $24.96 $154,720 - $213,832
8,567 Added 371.19%
10,875 $219,000
Q3 2018

Jul 13, 2023
BUY
$23.55 - $30.1 $153,286 - $195,920
6,509 Added 149.08%
10,875 $270 Million
Q3 2018

Nov 14, 2018
SELL
$23.55 - $30.1 $201,752 - $257,866
-8,567 Reduced 78.78%
2,308 $57,000
Q2 2018

Aug 15, 2018
BUY
$27.45 - $33.35 $61,268 - $74,437
2,232 Added 25.82%
10,875 $0
Q1 2018

May 15, 2018
BUY
$29.15 - $37.4 $32,239 - $41,364
1,106 Added 14.67%
8,643 $0
Q4 2017

Feb 15, 2018
SELL
$24.55 - $36.3 $198,486 - $293,485
-8,085 Reduced 51.75%
7,537 $269,000
Q2 2017

Aug 14, 2017
BUY
N/A
15,622
15,622 $412,000

Others Institutions Holding RVNC

# of Institutions
214
Shares Held
83.4M
Call Options Held
656K
Put Options Held
424K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email